Search Results
Your search for ,ITS matches 8694 pages
Showing 7051 - 7100Statement by ASCO President Clifford A. Hudis, MD, FACP, on ACS Report
“The American Cancer Society [recently] issued a report showing a 20% decline in cancer death rates between 1991 and 2010, and estimating that 1.3 million deaths have been averted as a result of the decline. “This is tremendous progress and a direct result of our nation’s commitment to cancer...
Overcoming Drug Development Challenges in the New Era of Cancer Care
While the last 15 years have brought unprecedented advances in oncology drug development, the next 10 years promise to usher in even greater opportunities to realize the goal of precision medicine in the treatment of cancer, providing patients with more effective care and better outcomes. Reaching...
Julie M. Vose, MD, MBA, FASCO, Elected ASCO President for 2015–2016 Term
Julie M. Vose, MD, MBA, FASCO, has been elected President of ASCO for a 1-year term beginning in June 2015. She will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2014. “ASCO is a very diverse and multifaceted organization with so much to offer its membership. The ...
The Conquer Cancer Foundation Celebrates 15 Years of Funding ASCO and Cancer Progress
While ASCO celebrates its 50th anniversary in 2014, the Conquer Cancer Foundation is also marking a milestone: its 15th anniversary and longtime dedication to improving the lives of people who have been touched by cancer. To accelerate progress against cancer, ASCO established the Foundation in...
ASCO Celebrates 50 Years of Advancing Progress Against Cancer
Fifty years ago, cancer was viewed as a monolithic and largely untreatable disease, with only a handful of hard-to-tolerate and mostly ineffective therapies available. Stigma and silence left many patients with cancer with little support or information. Determined to change this, a group of seven...
Ongoing NCI-Funded Clinical Trials Actively Recruiting Patients With Advanced Cancer
This issue of The ASCO Post launches a Clinical Trials Resource Guide to increase awareness of NCI-funded phase I, II, and III clinical studies for your patients with advanced cancer. All of the studies are listed on the National Institutes of Health website at ClinicalTrials.gov. The clinical...
American Lung Association Applauds U.S. Preventive Services Task Force Recommendation of Screening for Those at High Risk of Lung Cancer
The American Lung Association issued the following statement on December 31, 2013, in response to the recommendation of the U.S. Preventive Services Task Force (USPSTF) to screen individuals at high risk of lung cancer. “The [USPSTF] made a recommendation that will save lives. The Task Force...
Molecularly Targeted Therapy for Lung Cancer
INSIDE THE BLACK BOX is an occasional column offering insight into the FDA and its policies and procedures. This installment addresses a changing paradigm in the treatment of lung cancer, exemplified by concurrent approval of a companion diagnostic with each of several new targeted agents or new...
IFM 2005-02 Update Differs From CALGB 100104: Why?
The updated analysis of the Intergroupe Francophone du Myelome (IFM) 2005-02 trial in newly diagnosed multiple myeloma patients showed that lenalidomide (Revlimid) maintenance prolongs progression-free survival after stem cell transplantation, but does not improve overall survival, according to...
Can Postoperative Radiotherapy Be Avoided in Older Women With Early Breast Cancer and High Estrogen Receptor Expression?
A more conservative approach that avoids radiation therapy seems to be a reasonable option for a subgroup of older women with hormone receptor–positive breast cancer at low risk of recurrence. Overall outcomes were similar with or without radiation in older women with hormone receptor–positive...
HER2-Positive Breast Cancer Patients With Small Tumors Benefit From Low-Toxicity Regimen
There may be a benefit for treating small HER2-positive tumors—a breast cancer subset for whom treatment recommendations have not been established but for whom there is still risk of recurrence—and this can be done with little toxicity, according to a multicenter study presented at the 2013 San...
Seven Studies at SABCS Make Dr. Jame Abraham's List of 'Practice-Changing' Talks
From December 10 to 14, the American Association for Cancer Research, the Cancer Therapy & Research Center at The University of Texas Health Sciences Center at San Antonio, and Baylor College of Medicine once again hosted the San Antonio Breast Cancer Symposium (SABCS), presenting...
Philips Receives FDA Clearance for Spectral Breast Density Measurement Application
Royal Philips has announced that that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Spectral Breast Density Management Application for its MicroDose SI full-field digital mammography system. The application is the first spectral breast density measurement ...
International Society of Geriatric Oncology Meeting Explores Multidisciplinary, Tailored Treatment of Older Patients With Cancer
The annual meeting of the International Society of Geriatric Oncology (SIOG, www.siog.org) was held in Copenhagen from October 24 to 26. The theme of the meeting was the “Multidisciplinary Approach Towards Personalized Treatments.” The Society, which was founded in 2000, is a multidisciplinary...
Anastrozole Halves Risk of First Breast Cancer in High-Risk Postmenopausal Women
Five years of treatment with anastrozole reduced the risk of breast cancer by 53% in postmenopausal women at high risk for developing the disease, according to an analysis of the International Breast Cancer Intervention Study (IBIS)-II trial. Anastrozole reduced the risk of estrogen...
Mounting Success in Trials of Genetically Engineered T Cells to Treat Leukemias and Lymphomas
Reports have been trickling in from centers conducting research on the use of chimeric antigen receptor–modified T cells (CAR-T) in hematologic cancer, and the news is encouraging. When directed against CD19, such personalized therapeutic T cells are known as CTL019, and small pilot trials of this...
ASCO's 50th Anniversary and the Road Ahead
As the American Society of Clinical Oncology celebrates its 50th anniversary, ASCO’s Chief Executive Officer Allen S. Lichter, MD, FASCO, recently talked with The ASCO Post about the Society’s past, present, and future. Important Milestone What are your thoughts about ASCO’s origins and its 50th...
Risk-Based Breast Cancer Screening: Studies Suggest Alternatives to Age-Based Guidelines
Measuring certain hormone levels could help determine a woman’s risk for breast cancer and add a key factor to current risk-prediction models, according to investigators from Harvard Medical School. Their new study results were presented at the American Association for Cancer Research (AACR) Annual ...
Continuous Lenalidomide/Low-Dose Dexamethasone: A New Option for Older Patients With Newly Diagnosed Myeloma
First-line treatment of newly diagnosed multiple myeloma using the Rd regimen (continuous lenalidomide [Revlimid] plus low-dose dexamethasone) was superior to standard triplet treatment with MPT (melphalan, prednisone, and thalidomide [Thalomid]) for 72 weeks, according to initial results of the...
An Overview of the REGAL Trial and Anti-VEGF Therapies in Recurrent Glioblastoma
As published in the Journal of Clinical Oncology by Batchelor and colleagues1 and reviewed in a recent issue of The ASCO Post (November 15, 2013, page 106), the REGAL trial was a randomized, phase III, placebo-controlled, partially blinded trial evaluating the efficacy of cediranib, an...
Reports From the IPOS/AORTIC Travel Scholars
Eight individuals were awarded travel scholarships allowing them to attend the IPOS/AORTIC Program (International Psycho-Oncology Society/African Organization for Research and Training in Cancer) and share their experiences and efforts toward improving the psychosocial care of patients with cancer...
50th Anniversary of the First U.S. Surgeon General’s Report on Smoking and Health
“When the first Surgeon General’s Report was released in 1964, more than half of American men and over a third of women smoked and lung cancer had gone from an obscure disease to a leading cause of death. In issuing this pioneering report summarizing the known health risks of smoking, our nation’s...
Cancer.Net’s Newest Resource—the Cancer.Net Blog
Starting this year, Cancer.Net added a new interactive blog to its list of resources. Using the blog, Cancer.Net will be able to share information in a more timely manner and respond to current events, including breaking news about cancer advances and other topics important to people affected by...
ASCO Cosponsors Inaugural Palliative Care in Oncology Symposium
In October, ASCO will cosponsor the inaugural Palliative Care in Oncology Symposium with the American Academy of Hospice and Palliative Medicine (AAHPM), the American Society for Radiation Oncology (ASTRO), and the Multinational Association of Supportive Care in Cancer (MASCC). The Symposium is...
ASCO Member Helps to Strengthen Cancer Care Internationally Through Philanthropy and Volunteer Service
Ian F. Tannock, MD, PhD, DSc, FASCO, Professor of Medical Oncology at Princess Margaret Hospital and University of Toronto, has long been an advocate for ASCO as a truly global society and a leader in cancer care worldwide. It’s something he encouraged during his time on ASCO’s Board of Directors,...
ASCO President Issues Statement on Major Decline in Lung Cancer
Editor’s note: The Centers for Disease Control and Prevention (CDC) recently issued a report on lung cancer incidence trends in the United States.1 According to the report, incidence rates for lung cancer have decreased between 2005 and 2009, the period evaluated. Lung cancer incidence has...
Lung Cancer Screening Facts
The U.S. Preventive Services Task Force has posted a supplemental fact sheet for clinicians on its final recommendation statement on screening for lung cancer.1 This resource is meant to help health-care professionals talk about lung cancer screening with their patients and determine if screening...
Common Mutations May Impact Neoadjuvant Treatment Outcomes in Breast Cancer
Emerging research is suggesting that outcomes from neoadjuvant chemotherapy may be correlated with two genetic mutations that are common in breast cancer—PIK3CA and TP53. Their presence may affect response to treatment, and mutational shift after treatment may affect survival, according to studies...
Expert Point of View: Andrew D. Zelenetz, MD, PhD
Andrew D. Zelenetz, MD, PhD, Chair of the Non-Hodgkin Lymphoma Guideline Panel of the National Comprehensive Cancer Network (NCCN) and former Chief of the Lymphoma Service at Memorial Sloan-Kettering Cancer Center, New York, commented on the study by Yamshon et al for The ASCO Post. He said the...
Cancer Genes, Promiscuity, and the National Debt
There is no doubt that this is a halcyon period in oncology. The unraveling of the genome has been tremendously important, and finally has helped us to move treatment selection from an era of rational empiricism to one of refined, molecular prognostication. In the care of breast cancer, the impact...
Major Cancer Advances in 2013 Highlight Importance of Federal Funding
About one-third of the most important clinical advances in cancer last year were made possible at least in part through federal funding, according to ASCO’s annual report on progress in cancer, published in the Journal of Clinical Oncology.1 Significant Declines in Funding The report, “Clinical...
Addition of Carboplatin to Standard Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Supported by SABCS Studies
The achievement of a pathologic complete response in patients with triple-negative breast cancer was boosted by the addition of carboplatin to a standard neoadjuvant chemotherapy regimen, and by the addition of veliparib, an investigational oral PARP inhibitor, plus carboplatin to a standard...
Leukemia/Lymphoma Pioneer Geoffrey P. Herzig, MD, Dies
Many of the advances that have bettered mankind are attributed to those who were driven by a primary passion. Geoffrey P. Herzig, MD, lived the better part of his life with a primary passion: conducting research to increase the cure rate of leukemia and lymphoma patients. His friend and colleague,...
CYB5A Induces Autophagy, and Higher Expression Improves Survival in Pancreatic Cancer
Loss of 18q22.3 is a prognostic marker in pancreatic ductal adenocarcinoma. In a study reported in the Journal of the National Cancer Institute, Giovannetti and colleagues assessed the role of 18q22.3-encoded CYB5A in pancreatic cancer prognosis and autophagy modulation. In the study, both resected ...
Intact Gut Microbe Populations Improve Response to Chemotherapy
Gut microflora affect local and systemic inflammatory responses, and inflammation is involved in both pathogenesis and treatment of cancers, but it is unclear whether gut microflora affect inflammation in the sterile tumor microenvironment. In a study reported in Science, Iida and colleagues...
Confronting Uncertainty About the Harms and Benefits of Screening Mammography
“If women are to truly participate in the decision of whether or not to be screened [for breast cancer using mammography], they need some quantification of its benefits and harms,” asserted H. Gilbert Welch, MD, MPH, Professor of Medicine, and Honor J. Passow, PhD, Instructor, at The Dartmouth...
Nothing Prepared Me for Cancer
Fourteen years ago, when I was just 29, I was feeling weak and fatigued and had severe pain in my abdomen. I’d had these symptoms for about a year, but none of the several doctors I saw or any of the tests they performed could find the source of my problems. I even had one nurse practitioner tell...
Lessons Learned in Cancer Care Communication
Over the past several decades, outcomes data have traced the success stories in cancer research and therapeutics. However, during those decades of increasingly rapid scientific breakthroughs, certain psychosocial components in the continuum of cancer care were often overlooked. One such element is...
NIH Names First Chief Officer for Scientific Workforce Diversity, Hannah Valantine, MD
National Institutes of Health (NIH) Director Francis S. Collins, MD, PhD, has appointed Hannah Valantine, MD, to Chief Officer for Scientific Workforce Diversity. Dr. Valantine will lead NIH’s effort to diversify the biomedical research workforce by developing a vision and comprehensive strategy...
Kava
Kava Scientific Name: Piper methysticum Common Names: Kava-kava, kawa, kavain, rauschpfeffer, intoxicating long pepper, tonga, yagona, and yaqona. Overview Kava, a perennial shrub indigenous to the Hawaiian Islands and the Pacific Rim, is known for its relaxant effects and used for social and...
Ongoing NCI-Funded Clinical Trials Actively Recruiting Patients With Hematologic Cancers: Multiple Myeloma
Study Type: Non-Randomized Phase I/Interventional Study Title: Multicenter Phase I Study of Th1/Tc1 Immunotherapy Following Autologous Hematopoietic Progenitor Cell Transplantation in High-Risk Multiple Myeloma Study Sponsor and Collaborators: National Cancer Institute; Hackensack University...
Richard J. Gannotta, DHA, FACHE, Named President Northwestern Memorial Hospital
Northwestern Memorial HealthCare (NMHC) has announced that it has named Richard J. Gannotta, DHA, FACHE, President, Northwestern Memorial Hospital and Senior Vice President, NMHC effective this month. Dr. Gannotta was President of Duke Raleigh Hospital of the Duke University Health System. “Rick is ...
An Early Chemotherapy Innovator, Franco M. Muggia, MD, Now Focuses on Advancing Therapies for Ovarian Cancer
Looking over an illustrious career in medical oncology that spans 5 decades, Franco M. Muggia, MD, told The ASCO Post that he is excited about the future and hopes to continue making contributions to the field of oncology in years to come. At the forefront of the early clinical development of...
Focus on the Michigan Society of Hematology and Oncology
Founded nearly 3 decades ago in response to unfavorable changes in Medicare reimbursement regulations and growing coverage issues with Michigan’s private payers that threatened oncologists’ ability to provide quality cancer care to patients, the Michigan Society of Hematology and Oncology (MSHO)...
Milestones in Oncology, From ASCO’s CancerProgress.Net
To help tell the story of progress against cancer, ASCO launched CancerProgress.Net in 2011. The site is intended as a resource for media, policymakers, oncologists, advocates, and the public. One central feature of the site is an interactive timeline of major milestones in cancer treatment,...
FDA Programs to Expedite Drug and Biologic Product Development
With the advent of Breakthrough Therapy designation, there are now four FDA programs to expedite the development of promising new agents: Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval (Table 1). These programs complement one another and serve a common goal: to speed...
Radiation Oncology Institute Awards $200,000 Grant to Christopher Slatore, MD
The Radiation Oncology Institute (ROI) has named Christopher G. Slatore, MD, recipient of a $200,000 award, distributed over 2 years, for a project to examine the comparative value of radiation therapy and patient outcomes among patients with lung cancer. Dr. Slatore is Assistant Professor in the...
NIH Makes Palliative Care More Attainable for Pediatric Patients and Their Families
A campaign “Palliative Care: Conversations Matter” recently launched by the National Institute of Nursing Research (NINR) aims to increase the use of palliative care for children with serious illness. Palliative care can reduce a child’s pain, help manage other distressing symptoms, and provide...
Charting the Successes: CancerProgress.Net Chronicles More Than 50 Years of ASCO and Progress Against Cancer
On this historic year, as ASCO proudly commemorates its 50th anniversary and decades of evolutionary change and growth, it also celebrates the significant progress that has been made against cancer throughout history. ASCO’s anniversary website, CancerProgress.Net, chronicles these achievements and ...
ASCO Turns Attention to Community Researchers With Community Research Forum
The implementation of clinical trials and quality research programs by community-based investigators and research staff is one of the most effective weapons available in the fight against cancer. The ASCO Community Research Forum was designed in support of this mission and to aid these...
